Deregulation of the cell cycle is a hallmark of cancer that enables limitless cell division. To
support this malignant phenotype, cells acquire molecular alterations that abrogate or …

Inhibitors of mitotic protein kinases are currently being developed as non-neurotoxic
alternatives of microtubule-targeting agents (taxanes, vinca alkaloids) which provide a …

Genomic instability is a hallmark of cancer, and has a central role in the initiation and
development of breast cancer,. The success of poly-ADP ribose polymerase inhibitors in the …

Polo-like kinases (Plks) are critical regulatory molecules during the cell cycle process. This
family has five members: Plk1, 2, 3, 4, and 5. Plk4 has been identified as a master regulator …

In spite of significant advancements of therapies for initial eradication of cancers, tumor
relapse remains a major challenge. It is for a long time known that polyploid malignant cells …

Chromosomal instability (CIN) is a hallmark of cancer and is associated with tumor cell
malignancy. CIN triggers a chain reaction in cells leading to chromosomal abnormalities …

The identification of individual or clusters of predictive genetic alterations might help in
defining the outcome of cancer treatment, allowing for the stratification of patients into …

Conclusions: We show that by targeting a centrosome regulator, PLK4, to activate the
cytosolic DNA sensing‐mediated immune response, CFI‐400945 effectively restrained …

Purpose Polo-like kinase 4 (PLK4) is a serine/threonine protein kinase that regulates
centriole duplication. PLK4 deregulation causes centrosome number abnormalities, mitotic …

Cyclin E, a regulatory subunit of cyclin-dependent kinase 2 (CDK2), is central to the initiation
of DNA replication at the G1/S checkpoint. Tight temporal control of cyclin E is essential to …